InSightec's ExAblate in Japan
This article was originally published in The Gray Sheet
Executive Summary
Israel-based InSightec's ExAblate uterine fibroid treatment device receives Japanese regulatory approval, the firm announces Jan. 13. The magnetic resonance-guided, focused ultrasound system is the only noninvasive uterine fibroid treatment approved for use in Japan, the company notes. ExAblate received U.S. and European marketing approval in 2004 and 2002, respectively. GE Healthcare, a partial owner of the private firm, will distribute the system in Japan